multiple sclerosis

MediciNova gets bounce after revealing clinical plan for MS therapy
MediciNova gets bounce after revealing clinical plan for MS therapy
BioCentury
MedicNova
clinical trials
ibudilast
multiple sclerosis
Flag link:
Atara Reports Initial Data for Multiple Sclerosis Candidate
Atara Reports Initial Data for Multiple Sclerosis Candidate
Yahoo/Zacks.com
Atara
ATA188
clinical trials
multiple sclerosis
Flag link:
Novartis wins Gilenya reprieve as judge blocks generics, for now
Novartis wins Gilenya reprieve as judge blocks generics, for now
Yahoo/Reuters
Novartis
generics
Gilenya
multiple sclerosis
Flag link:
Celgene can breathe a sigh of relief as FDA accepts once-spurned ozanimod application — setting a target date on a blockbuster decision
Celgene can breathe a sigh of relief as FDA accepts once-spurned ozanimod application — setting a target date on a blockbuster decision
Endpoints
Celgene
FDA
EMA
ozanimod
multiple sclerosis
Flag link:
Troubled Biogen shows off its me-better approach to MS on PhIII update — but is it really just a patent play?
Troubled Biogen shows off its me-better approach to MS on PhIII update — but is it really just a patent play?
Endpoints
Biogen
MS
multiple sclerosis
Tecfidera
ALKS 8700
Vumerity
Alkermes
Flag link:
Upcoming events – key tests approach for Biogen and Kalvista
Upcoming events – key tests approach for Biogen and Kalvista
EP Vantage
Biogen
BIIB098
Tecfidera
multiple sclerosis
KalVista
HAE
Biocryst
BCX7353
KVD900
Flag link:
Upcoming events – Phase III data for Chiasma and Novartis
Upcoming events – Phase III data for Chiasma and Novartis
EP Vantage
Chiasma
acromegaly
Mycapssa
clinical trials
multiple sclerosis
Novartis
ofatumumab
Flag link:
Sanofi Joins Drugmakers' Bid to Treat Patients With Software
Sanofi Joins Drugmakers' Bid to Treat Patients With Software
Yahoo/Bloomberg
Sanofi
digital pharma
Happify Health
digital therapeutics
depression
multiple sclerosis
Flag link:
Pushing hard for blockbuster returns, Novartis finds PhIII data to assert Mayzent boosts cognitive powers in MS patients
Pushing hard for blockbuster returns, Novartis finds PhIII data to assert Mayzent boosts cognitive powers in MS patients
Endpoints
Novartis
Mayzent
siponimod
multiple sclerosis
Flag link:
FDA Raises Concerns With Novartis in Clinical Inspection
FDA Raises Concerns With Novartis in Clinical Inspection
RAPS.org
Novartis
FDA
Mayzent
siponimod
clinical trials
multiple sclerosis
Flag link:
German Merck finally gets yes for MS drug Mavenclad
German Merck finally gets yes for MS drug Mavenclad
Biopharma Dive
FDA
Merck KGaA
Mavenclad
MS
multiple sclerosis
Flag link:
Still hunting a blockbuster, Merck KGaA scores a win in the FDA approval column — more than 13 years in the making
Still hunting a blockbuster, Merck KGaA scores a win in the FDA approval column — more than 13 years in the making
Endpoints
FDA
Merck KGaA
cladribine
MA
multiple sclerosis
Flag link:
Celgene refiles ozanimod with FDA 1 year after regulatory snafu
Celgene refiles ozanimod with FDA 1 year after regulatory snafu
Fierce Biotech
Celgene
ozanimod
MS
multiple sclerosis
Flag link:
How This Looming Patent Battle Could Challenge Bristol-Celgene Deal
How This Looming Patent Battle Could Challenge Bristol-Celgene Deal
Investors Business Daily
Celgene
Novartis
ozanimod
MS
multiple sclerosis
patents
Bristol-Myers Squibb
M&A
Flag link:
Celgene Submits MS Drug for Approval in Europe, FDA Filing on Track
Celgene Submits MS Drug for Approval in Europe, FDA Filing on Track
Xconomy
Celgene
Bristol-Myers Squibb
Europe
FDA
M&A
MS
multiple sclerosis
ozanimod
Flag link:
FDA Accepts for Review Alkermes' and Biogen's NDA for Multiple Sclerosis Drug
FDA Accepts for Review Alkermes' and Biogen's NDA for Multiple Sclerosis Drug
CP WIre
Alkermes
Biogen
diroximel fumarate
MS
multiple sclerosis
Flag link:
Blocking brain inflammation in multiple sclerosis with gut immune cells
Blocking brain inflammation in multiple sclerosis with gut immune cells
Fierce Biotech
inflammation
MS
multiple sclerosis
Flag link:
Alkermes/Biogen hope for less tummy trouble with new MS pill
Alkermes/Biogen hope for less tummy trouble with new MS pill
Pharmaforum
Alkermes
Biogen
MS
multiple sclerosis
Vumerity
Flag link:
Novartis confident in Gilenya despite FDA call out
Novartis confident in Gilenya despite FDA call out
Biopharma Dive
Novartis
Gilenya
MS
multiple sclerosis
Flag link:
Mylan's generic Copaxone wins in court, but market barriers remain
Mylan's generic Copaxone wins in court, but market barriers remain
Biopharma Dive
Teva Pharmaceutical
Copaxone
patents
MS
multiple sclerosis
Flag link:

Pages